Search

Your search keyword '"Geethakumari, Praveen Ramakrishnan"' showing total 152 results
Start Over Author "Geethakumari, Praveen Ramakrishnan"
152 results on '"Geethakumari, Praveen Ramakrishnan"'

1. List of Contributors

Author

Rahman, Zaid Abdel, primary, Abutalib, Syed Ali, additional, Afrough, Aimaz, additional, Ahmed, Sairah, additional, Al-Juhaishi, Taha, additional, Alousi, Amin M, additional, Alsfeld, Leonard C., additional, Awan, Farrukh T., additional, Azhar, Ahsan, additional, Bashir, Qaiser, additional, Brown, Brandon Douglas, additional, Cao, Kai, additional, Champlin, Richard E., additional, Cherng, Hua-Jay J., additional, Ciurea, Stefan O., additional, Dabaja, Bouthaina, additional, Daher, May, additional, De Lima, Marcos, additional, Dillard, Christen M., additional, Fang, Penny, additional, Viña, Marcelo A. Fernández, additional, Ferreri, Christopher James, additional, Furqan, Fateeha, additional, Gagelmann, Nico, additional, Geethakumari, Praveen Ramakrishnan, additional, Ghanem, Sassine, additional, Greenbaum, Uri, additional, Gulbis, Alison M., additional, Haider, Ali, additional, Hamadani, Mehdi, additional, Handy, Victoria Wehr, additional, Hawkins, Misha C., additional, Heredia, Ella J. Ariza, additional, Hosing, Chitra, additional, Im, Jin Seon, additional, Jain, Nitin, additional, Jallouk, Andrew P, additional, Jankowski, Mika L., additional, Kale, Brandon J., additional, Kebriaei, Partow, additional, Khalil, Lana, additional, Khan, Irum, additional, Khazal, Sajad, additional, Kongtim, Piyanuch, additional, Lin, Paul, additional, Mahadeo, Kris M., additional, Malek, Alexandre E, additional, McGee, Kara, additional, Mehta, Rohtesh S., additional, Mulanovich, Victor Eduardo, additional, Munshi, Pashna N., additional, Nastoupil, Loretta J., additional, Neelapu, Sattva S, additional, Nieto, Yago, additional, Olson, Amanda, additional, Oran, Betul, additional, Otegbeye, Folashade, additional, Patel, Akshat Maneesh, additional, Patel, Krina, additional, Paul, Prince, additional, Pemmaraju, Naveen, additional, Popat, Uday R, additional, Qazilbash, Muzaffar H., additional, Rafei, Hind, additional, Ragoonanan, Dristhi S, additional, Ramdial, Jeremy L., additional, Rezvani, Katayoun, additional, Rodriguez, Ana Avila, additional, Rondón, Gabriela, additional, Saengboon, Supawee, additional, Sanchez-Petitto, Gabriela, additional, Shigle, Terri Lynn, additional, Shpall, Elizabeth J., additional, Srour, Samer A., additional, Steiner, Raphael E., additional, Stolar, Karen R., additional, Strati, Paolo, additional, Szewczyk, Nicholas A., additional, Tanner, Mark R., additional, Tang, Kevin, additional, Thall, Peter F., additional, Tummala, Sudhakar, additional, Uzoka, Chukwuemeka, additional, Wallis, Whitney D., additional, Westin, Jason R., additional, Wilson, Nathaniel R., additional, Wu, Susan, additional, Guevara, Eduardo Yepez, additional, and Zou, Jun, additional

Published
2024
Full Text
View/download PDF

2. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study

Author

Epperla, Narendranath, Welkie, Rina Li, Torka, Pallawi, Shouse, Geoffrey, Karmali, Reem, Shea, Lauren, Anampa-Guzmán, Andrea, Oh, Timothy S., Reaves, Heather, Tavakkoli, Montreh, Lindsey, Kathryn, Greenwell, Irl Brian, Hansinger, Emily, Thomas, Colin, Chowdhury, Sayan Mullick, Annunzio, Kaitlin, Christian, Beth, Barta, Stefan K., Geethakumari, Praveen Ramakrishnan, Bartlett, Nancy L., Herrera, Alex F., Grover, Natalie S., and Olszewski, Adam J.

Published
2023
Full Text
View/download PDF

4. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study

Author

Epperla, Narendranath, Zhao, Qiuhong, Karmali, Reem, Torka, Pallawi, Shea, Lauren, Oh, Timothy S., Anampa-Guzmán, Andrea, Reves, Heather, Tavakkoli, Montreh, Greenwell, Irl Brian, Hansinger, Emily, Umyarova, Elvira, Annunzio, Kaitlin, Sawalha, Yazeed, Christian, Beth, Thomas, Colin, Barta, Stefan K., Geethakumari, Praveen Ramakrishnan, Bartlett, Nancy L., Grover, Natalie S., and Olszewski, Adam J.

Published
2023
Full Text
View/download PDF

6. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

Author

Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., and Shouse, Geoffrey

Published
2022
Full Text
View/download PDF

7. Identification of Pre-Treatment Clinical Risk Factors Predictive of Inferior Survival and Increased Risk of Treatment Failure in CD19 Chimeric Antigen Receptor T Cell Recipients with Large B Cell Lymphoma.

Author

Geethakumari, Praveen Ramakrishnan, primary, Wudhikarn, Kitsada, additional, Jain, Michael D., additional, Vallurupalli, Anusha, additional, Kim, Soyoung, additional, Oloyede, Temitope, additional, Awan, Farrukh T, additional, Mirza, Abu-Sayeef, additional, Bachanova, Veronika, additional, Badar, Talha, additional, Barba, Pere, additional, Beitinjaneh, Prof. Amer, additional, Cashen, Amanda, additional, Dholaria, Dr. Bhagirathbhai, additional, Elsawy, Mahmoud, additional, Farooq, Umar, additional, Foglesong, Jessica, additional, Ganguly, Siddhartha MD, additional, Greenbaum, Uri, additional, Hashmi, Hamza, additional, Hill, LaQuisa Chimere, additional, Jain, Dr. Tania, additional, Kebriaei, Partow, additional, Kittai, Adam S., additional, Locke, Frederick L., additional, Lulla, Premal D., additional, Mead, Elena, additional, McGuirk, Joseph P, additional, Mussetti, Alberto, additional, Nishihori, Taiga, additional, Olson, Amanda L., additional, Pennisi, Martina, additional, Perales, Miguel-Angel, additional, Riedell, Peter A., additional, Saber, Wael, additional, Shouval, Roni, additional, Shpall, Elizabeth J., additional, Sorror, Mohamed L., additional, Strouse, Christopher Sun, additional, Turtle, Cameron J., additional, Pasquini, Marcelo C., additional, Moskop, Amy, additional, and Ahmed, Sairah, additional

Published
2024
Full Text
View/download PDF

8. Assessing the Predictive Value of Pre-Lymphodepletion and Infusion Endothelial Activation and Stress Index in CD19-Directed CAR-T Therapy for B-Cell Lymphoma

Author

Upreti, Harsh Vardhan, primary, Lee, Jimmy, additional, Sannareddy, Aishwarya, additional, Reves, Heather, additional, Turer, Laura, additional, Abraham, Pearl, additional, Liu, Yulun, additional, Yilmaz, Elif, additional, Wolfe, Heather, additional, Kaur, Gurbakhash, additional, Khan, Adeel, additional, Madanat, Yazan F., additional, Thiebaud, Julio Alvarenga, additional, Velarde, Alejandro Marino, additional, Collins, Robert H., additional, Chung, Stephen, additional, Geethakumari, Praveen Ramakrishnan, additional, Anderson, Larry D., additional, Awan, Farrukh T, additional, Afrough, Aimaz, additional, and Anderson, Julia Marie, additional

Published
2024
Full Text
View/download PDF

9. Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single Center Retrospective Analysis.

Author

Sannareddy, Aishwarya, primary, Lee, Jimmy, additional, Upreti, Harsh Vardhan, additional, Turer, Laura, additional, Anderson, Julia Marie, additional, Reves, Heather, additional, Gaines, Kailee, additional, Patel, Hetalkumari, additional, Abraham, Pearl, additional, Jones, Ashley, additional, Yn, Alicia, additional, Eze, Ebubechukwu, additional, Chong, Pearlie, additional, Tessier, Jeffrey, additional, Chung, Stephen, additional, Collins, Robert H., additional, Madanat, Yazan F., additional, Wolfe, Heather, additional, Yilmaz, Elif, additional, Thiebaud, Julio Alvarenga, additional, Geethakumari, Praveen Ramakrishnan, additional, Kaur, Gurbakhash, additional, Khan, Adeel, additional, Anderson, Larry D., additional, Awan, Farrukh T, additional, La Hoz, Ricardo, additional, and Afrough, Aimaz, additional

Published
2024
Full Text
View/download PDF

11. Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Data1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

13. Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

14. Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

15. Data from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

16. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience

Author

Hoff, Fieke W., primary, Chung, Stephen S., additional, Patel, Prapti A., additional, Premnath, Naveen, additional, Khatib, Jude, additional, Tadic-Ovcina, Mirjana, additional, AhmedRabie, Abeer, additional, Helton, Debra, additional, Yohannes, Selamawit, additional, Shahan, Jaime, additional, Patel, Hetalkumari, additional, Geethakumari, Praveen Ramakrishnan, additional, Vusirikala, Madhuri, additional, Collins, Robert H., additional, and Madanat, Yazan F., additional

Published
2023
Full Text
View/download PDF

17. Postibrutinib Relapse Outcomes for Patients with Marginal Zone Lymphoma

Author

Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Xiao-Wei Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Oh, Timothy S., Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., Shouse, Geoffrey, Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Xiao-Wei Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Oh, Timothy S., Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., and Shouse, Geoffrey

Published
2023

18. Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., additional, William, Basem M., additional, Brammer, Jonathan E., additional, Smith, Sonali M., additional, Prica, Anca, additional, Zain, Jasmine M., additional, Tuscano, Joseph M., additional, Shah, Harsh, additional, Mehta-Shah, Neha, additional, Geethakumari, Praveen Ramakrishnan, additional, Wang, Ben X., additional, Zantinge, Stephanie, additional, Wang, Lisa, additional, Zhang, Ling, additional, Boutrin, Anmarie, additional, Zhao, Weiguang, additional, Cheng, Lily, additional, Standifer, Nathan, additional, Hewitt, Lisa, additional, Enowtambong, Enowmpey, additional, Shao, Weiping, additional, Sharma, Shringi, additional, Carlesso, Gianluca, additional, Moscow, Jeffrey A., additional, and Siu, Lillian L., additional

Published
2023
Full Text
View/download PDF

19. Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort

Author

Premnath, Naveen, primary, Chung, Stephen S., additional, Weinberg, Olga K., additional, Ikpefan, Ruth, additional, Pandey, Mohak, additional, Kaur, Gurbakhash, additional, Geethakumari, Praveen Ramakrishnan, additional, Afrough, Aimaz, additional, Awan, Farrukh T., additional, Anderson, Larry D., additional, Vusirikala, Madhuri, additional, Collins, Robert H., additional, Chen, Weina, additional, Agathocleous, Michalis, additional, and Madanat, Yazan F., additional

Published
2023
Full Text
View/download PDF

20. Infectious Complications Post-CAR T-Cell Therapy for Lymphomas: Impact of Bridging Therapy

Author

Lue, Brian Ko-Hung, primary, Patel, Akshat Maneesh, additional, Reves, Heather, additional, Afrough, Aimaz, additional, Anderson, Larry D., additional, Chung, Stephen, additional, Collins, Robert H., additional, Kaur, Gurbakhash, additional, Kumar, Kiran, additional, Madanat, Yazan F., additional, Vusirikala, Madhuri, additional, Awan, Farrukh T, additional, Tessier, Jeffrey M, additional, and Geethakumari, Praveen Ramakrishnan, additional

Published
2023
Full Text
View/download PDF

21. Impact of Autologous Hematopoietic Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL): A ‘Real-World’ Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

Author

Reves, Heather, primary, Jackson, Meredith, additional, Prasad, Tanushree, additional, Afrough, Aimaz, additional, Anderson, Larry D., additional, Collins, Robert H., additional, Kaur, Gurbakhash, additional, Wolfe, Heather, additional, Yilmaz, Elif, additional, Khan, Adeel, additional, Kumar, Kiran, additional, Madanat, Yazan F., additional, Vusirikala, Madhuri, additional, Awan, Farrukh T, additional, and Geethakumari, Praveen Ramakrishnan, additional

Published
2023
Full Text
View/download PDF

22. ‘Real-World’ Impact of Tixagevimab/Cilgavimab (Evusheld) on COVID-19 Outcomes in Patients Undergoing Cellular Therapies

Author

Sannareddy, Aishwarya, primary, Reves, Heather, additional, Narasimhan, Madhusudhanan, additional, Jaleta, Kefyalew, additional, Anderson, Julia Marie, additional, Patel, Hetalkumari, additional, Anderson, Larry D., additional, Afrough, Aimaz, additional, Chung, Stephen, additional, Collins, Robert H., additional, Kaur, Gurbakhash, additional, Kumar, Kiran A, additional, Madanat, Yazan F., additional, Vusirikala, Madhuri, additional, Awan, Farrukh T, additional, Muthukumar, Alagar R, additional, and Geethakumari, Praveen Ramakrishnan, additional

Published
2023
Full Text
View/download PDF

24. Postibrutinib relapse outcomes for patients with marginal zone lymphoma

Author

Epperla, Narendranath, primary, Zhao, Qiuhong, additional, Chowdhury, Sayan Mullick, additional, Shea, Lauren, additional, Moyo, Tamara K., additional, Reddy, Nishitha, additional, Sheets, Julia, additional, Weiner, David M., additional, Geethakumari, Praveen Ramakrishnan, additional, Kandarpa, Malathi, additional, Bruno, Ximena Jordan, additional, Thomas, Colin, additional, Churnetski, Michael C., additional, Hsu, Andrew, additional, Zurbriggen, Luke, additional, Tan, Xiao-wei Cherie, additional, Lindsey, Kathryn, additional, Maakaron, Joseph, additional, Caimi, Paolo F., additional, Torka, Pallawi, additional, Bello, Celeste, additional, Ayyappan, Sabarish, additional, Oh, Timothy S., additional, Karmali, Reem, additional, Kim, Seo-Hyun, additional, Kress, Anna, additional, Kothari, Shalin, additional, Sawalha, Yazeed, additional, Christian, Beth, additional, David, Kevin A., additional, Greenwell, Irl Brian, additional, Janakiram, Murali, additional, Kenkre, Vaishalee P., additional, Olszewski, Adam J., additional, Cohen, Jonathon B., additional, Palmisiano, Neil, additional, Umyarova, Elvira, additional, Wilcox, Ryan A., additional, Awan, Farrukh T., additional, Alderuccio, Juan Pablo, additional, Barta, Stefan K., additional, Grover, Natalie S., additional, Ghosh, Nilanjan, additional, Bartlett, Nancy L., additional, Herrera, Alex F., additional, and Shouse, Geoffrey, additional

Published
2023
Full Text
View/download PDF

25. Additional file 1 of Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study

Author

Epperla, Narendranath, Welkie, Rina Li, Torka, Pallawi, Shouse, Geoffrey, Karmali, Reem, Shea, Lauren, Anampa-Guzmán, Andrea, Oh, Timothy S., Reaves, Heather, Tavakkoli, Montreh, Lindsey, Kathryn, Greenwell, Irl Brian, Hansinger, Emily, Thomas, Colin, Chowdhury, Sayan Mullick, Annunzio, Kaitlin, Christian, Beth, Barta, Stefan K., Geethakumari, Praveen Ramakrishnan, Bartlett, Nancy L., Herrera, Alex F., Grover, Natalie S., and Olszewski, Adam J.

Abstract

Additional file 1. Supplementary methods, results, tables and figures.

Published
2023
Full Text
View/download PDF

26. Supplemental Material - Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma

Author

Kapinos, Kandice A., Hu, Ellen, Trivedi, Jigar, Geethakumari, Praveen Ramakrishnan, and Kansagra, Ankit

Subjects
FOS: Clinical medicine, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental Material for Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma by Kandice A. Kapinos, Ellen Hu, Jigar Trivedi, Praveen Ramakrishnan Geethakumari, Ankit Kansagra in Cancer Control

Published
2023
Full Text
View/download PDF

27. Optimizing Palliative Focal Radiation Therapy Dose in Cutaneous T-Cell Lymphoma: How Low Can You Go?

Author

Patel, Akshat M., primary, West, Lindsey, additional, Atluri, Pramukh S., additional, Yi, Sofia F., additional, Rizvi, Syed, additional, Geethakumari, Praveen Ramakrishnan, additional, Awan, Farrukh T., additional, Chen, Weina, additional, Shah, Jennifer L., additional, Desai, Neil B., additional, Goff, Heather W., additional, and Kumar, Kiran A., additional

Published
2022
Full Text
View/download PDF

31. A phase 2, multicentre, open‐label trial ( ACE‐LY ‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma

Author

Strati, Paolo, primary, Coleman, Morton, additional, Champion, Rebecca, additional, Ma, Shuo, additional, Patti, Caterina, additional, Levy, Moshe Y., additional, Lossos, Izidore S., additional, Geethakumari, Praveen Ramakrishnan, additional, Lam, Selay, additional, Calvo, Roser, additional, Higgins, Kara, additional, and Budde, Lihua E., additional

Published
2022
Full Text
View/download PDF

32. Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).

Author

Villasboas, Jose Caetano, primary, Kline, Justin Paul, additional, Lazaryan, Aleksandr, additional, Bartlett, Nancy L., additional, Hernandez-Ilizaliturri, Francisco J., additional, Awan, Farrukh Tauseef, additional, Geethakumari, Praveen Ramakrishnan, additional, Karmali, Reem, additional, Shune, Leyla, additional, Lansigan, Frederick, additional, Reeder, Craig B., additional, Magid Diefenbach, Catherine S., additional, Sharon, Elad, additional, Atherton, Pamela J., additional, Fiskum, Jack, additional, Yin, Jun, additional, Adjei, Alex A., additional, and Ansell, Stephen M., additional

Published
2022
Full Text
View/download PDF

33. Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial.

Author

Budde, L Elizabeth, primary, Coleman, Morton, additional, Stevens, Don A., additional, Ma, Shuo, additional, Patti, Caterina, additional, Levy, M. Yair, additional, Lossos, Izidore S., additional, Geethakumari, Praveen Ramakrishnan, additional, Lam, Selay, additional, Calvo, Roser, additional, Higgins, Kara, additional, and Strati, Paolo, additional

Published
2022
Full Text
View/download PDF

34. Treatment Patterns, Outcomes and the Impact of Cellular Therapies in Secondary Central Nervous System Lymphoma (SCNSL): The UT Southwestern Experience

Author

Patel, Akshat Maneesh, primary, Muquith, Maishara, additional, Reves, Heather, additional, Patel, Hetalkumari, additional, Jaso, Jesse, additional, Chen, Weina, additional, Patel, Toral, additional, Desai, Neil, additional, Timmerman, Robert, additional, Kumar, Kiran, additional, Kainthla, Radhika, additional, Afrough, Aimaz, additional, Anderson Jr., Larry D., additional, Chung, Stephen, additional, Madanat, Yazan F., additional, Kaur, Gurbakhash, additional, Kansagra, Ankit, additional, Patel, Prapti, additional, Vusirikala, Madhuri, additional, Collins, Robert H., additional, Sweetenham, John W., additional, Awan, Farrukh T, additional, and Geethakumari, Praveen Ramakrishnan, additional

Published
2022
Full Text
View/download PDF

35. Pre-Lymphodepletion Endothelial Activation and Stress Index As a Predictor of Clinical Outcomes in B-Cell Maturation Antigen CAR T Therapy for Multiple Myeloma

Author

Lee, Jimmy, Upreti, Harsh Vardhan, Sannareddy, Aishwarya, Reves, Heather, Turer, Laura, Abraham, Pearl, Liu, Yulun, Yilmaz, Elif, Wolfe, Heather, Kaur, Gurbakhash, Khan, Adeel, Madanat, Yazan F., Thiebaud, Julio Alvarenga, Velarde, Alejandro Marino, Collins, Robert H., Chung, Stephen, Geethakumari, Praveen Ramakrishnan, Awan, Farrukh T, Anderson, Larry D., Jr., Afrough, Aimaz, and Anderson, Julia Marie

Published
2024
Full Text
View/download PDF

37. Primary Central Nervous System Lymphoma: A Real-World Comparison of Therapy Access and Outcomes by Hospital Setting

Author

Patel, Akshat Maneesh, primary, Ali, Omer, additional, Kainthla, Radhika, additional, Rizvi, Syed M., additional, Awan, Farrukh T., additional, Patel, Toral, additional, Pan, Edward, additional, Maher, Elizabeth, additional, Desai, Neil B., additional, Timmerman, Robert, additional, Kumar, Kiran A., additional, and Geethakumari, Praveen Ramakrishnan, additional

Published
2021
Full Text
View/download PDF

39. A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma.

Author

Alsuwaidan, Abdullah, Koduru, Prasad, Fuda, Franklin, Jaso, Jesse Manuel, Chen, Mingyi, Rosado, Flavia, Luu, Hung S, Sweed, Nathan, Garcia, Rolando, Doucet, Meggie, Desai, Neil B, Kumar, Kiran A, Awan, Farrukh T, Geethakumari, Praveen Ramakrishnan, Chen, Weina, Manuel Jaso, Jesse, and Ramakrishnan Geethakumari, Praveen

Subjects
PROTEINS, B cell lymphoma, FLUORESCENCE in situ hybridization, GENES
Abstract

Objectives: Diagnosis of high-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements (double-/triple-hit lymphoma [DTHL]) appears to mandate fluorescence in situ hybridization (FISH) testing for all large B-cell lymphoma (LBCL). Given the low incidence of DTHL, we aimed to identify flow cytometry (FC) and immunohistochemistry (IHC) features of DTHL that could be used to develop an optimal screening strategy. This combined FC-IHC approach has not yet been studied.Methods: We compared features of 40 cases of DTHL and 39 cases of diffuse LBCL (DLBCL) without MYC rearrangement.Results: Bright CD38 expression (CD38bright) by FC, high MYC expression (≥55%), and double-expressor phenotype by IHC were significantly associated with DTHL. The biomarker combining FC and IHC, CD38bright and/or MYC ≥55%, was superior to FC and IHC markers alone in predicting DTHL. Restricting FISH testing to approximately 25% of LBCL based on CD38brightand/or MYC ≥55% would detect approximately 95% of DTHL-BCL2 and approximately 75% of DHL-BCL6.Conclusions: Our study demonstrated that the novel biomarker of CD38bright and/or MYC ≥55% is highly predictive of DTHL. Awareness of the advantages and limitations of this screening strategy would facilitate development of a rational diagnostic workflow to provide high-quality patient care. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. P-111 Overall survival trends in young (

Author

Dong, Sharlene, Sannareddy, Aishwarya, Sankarasubramanian, Ramya, Reves, Heather, Khan, Umar, Sadeghi, Navid, Kainthla, Radhika, Khan, Adeel, Afrough, Aimaz, Wolfe, Heather, Madanat, Yazan, Geethakumari, Praveen Ramakrishnan, Yilmaz, Elif, Awan, Farrukh, Collins, Robert, Anderson, Larry, Li, Jenny, and Kaur, Gurbakhash

Published
2023
Full Text
View/download PDF

42. Primary central nervous system lymphoma: a real-world comparison of therapy access and outcomes by hospital setting.

Author

Patel, Akshat M, Ali, Omer, Kainthla, Radhika, Rizvi, Syed M, Awan, Farrukh T, Patel, Toral, Pan, Edward, Maher, Elizabeth, Desai, Neil B, Timmerman, Robert, Kumar, Kiran A, and Geethakumari, Praveen Ramakrishnan

Subjects
CENTRAL nervous system, STEM cell transplantation, PUBLIC hospitals, LYMPHOMAS, HEALTH services accessibility
Abstract

Background This study analyzes sociodemographic barriers for primary CNS lymphoma (PCNSL) treatment and outcomes at a public safety-net hospital versus a private tertiary academic institution. We hypothesized that these barriers would lead to access disparities and poorer outcomes in the safety-net population. Methods We reviewed records of PCNSL patients from 2007–2020 (n = 95) at a public safety-net hospital (n = 33) and a private academic center (n = 62) staffed by the same university. Demographics, treatment patterns, and outcomes were analyzed. Results Patients at the safety-net hospital were significantly younger, more commonly Black or Hispanic, and had a higher prevalence of HIV/AIDS. They were significantly less likely to receive induction chemotherapy (67% vs 86%, P =.003) or consolidation autologous stem cell transplantation (0% vs. 47%, P =.001), but received more whole-brain radiation therapy (35% vs 16%, P =.001). Younger age and receiving any consolidation therapy were associated with improved progression-free (PFS, P =.001) and overall survival (OS, P =.001). Hospital location had no statistical impact on PFS (P =.725) or OS (P =.226) on an age-adjusted analysis. Conclusions Our study shows significant differences in treatment patterns for PCNSL between a public safety-net hospital and an academic cancer center. A significant survival difference was not demonstrated, which is likely multifactorial, but likely was positively impacted by the shared multidisciplinary care delivery between the institutions. As personalized therapies for PCNSL are being developed, equitable access including clinical trials should be advocated for resource-limited settings. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. Lymphomatoid granulomatosis of the central nervous system (CNS-LYG), immune thrombocytopenia, disseminated zoster and venous thrombosis: “Hickam’s dictum posing a management challenge”

Author

Soleja, Mohsin, primary, Jaso, Jesse, additional, Chen, Weina, additional, Raisanen, Jack, additional, Wysocki, Christian, additional, Shen, Yu-Min, additional, Mickey, Bruce, additional, Kumar, Kiran, additional, and Geethakumari, Praveen Ramakrishnan, additional

Published
2021
Full Text
View/download PDF

44. Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation

Author

Jagadeesh, Deepa, Majhail, Navneet S., He, Yizeng, Ahn, Kwang W., Litovich, Carlos, Ahmed, Sairah, Aljurf, Mahmoud, Bacher, Ulrike, Badawy, Sherif M., Bejanyan, Nelli, Cairo, Mitchell, Cerny, Jan, Epperla, Narendranath, Farhadfar, Nosha, Freytes, Cesar O., Gale, Robert Peter, Haverkos, Bradley, Hossain, Nasheed, Inwards, David, Kamble, Rammurti T., Kenkre, Vaishalee P., Lazarus, Hillard M., Lazaryan, Aleksandr, Lekakis, Lazaros, Mei, Matthew, Murthy, Hemant S., Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard, Geethakumari, Praveen Ramakrishnan, Savani, Bipin N., Yared, Jean A., Fenske, Timothy S., Kharfan-Dabaja, Mohamed A., Sureda, Anna, Hamadani, Mehdi, Jagadeesh, Deepa, Majhail, Navneet S., He, Yizeng, Ahn, Kwang W., Litovich, Carlos, Ahmed, Sairah, Aljurf, Mahmoud, Bacher, Ulrike, Badawy, Sherif M., Bejanyan, Nelli, Cairo, Mitchell, Cerny, Jan, Epperla, Narendranath, Farhadfar, Nosha, Freytes, Cesar O., Gale, Robert Peter, Haverkos, Bradley, Hossain, Nasheed, Inwards, David, Kamble, Rammurti T., Kenkre, Vaishalee P., Lazarus, Hillard M., Lazaryan, Aleksandr, Lekakis, Lazaros, Mei, Matthew, Murthy, Hemant S., Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard, Geethakumari, Praveen Ramakrishnan, Savani, Bipin N., Yared, Jean A., Fenske, Timothy S., Kharfan-Dabaja, Mohamed A., Sureda, Anna, and Hamadani, Mehdi

Abstract

BACKGROUND Although rituximab-based high-dose therapy is frequently used in diffuse large B cell lymphoma (DLBCL) patients undergoing autologous hematopoietic cell transplantation (auto-HCT), data supporting the benefits are not available. Herein, we report the impact of rituximab-based conditioning on auto-HCT outcomes in patients who have DLBCL. METHODS Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, 862 adult DLBCL patients undergoing auto-HCT between 2003 and 2017 using BEAM (BCNU, etoposide, cytarabine, melphalan) conditioning regimen were included. All patients received frontline rituximab-containing chemoimmunotherapy and had chemosensitive disease pre-HCT. Early chemoimmunotherapy failure was defined as not achieving complete remission (CR) after frontline chemoimmunotherapy or relapse within 1 year of initial diagnosis. The primary outcome was overall survival (OS). RESULTS The study cohort was divided into 2 groups: BEAM (n = 667) and R-BEAM (n = 195). On multivariate analysis, no significant difference was seen in OS (P = .83) or progression-free survival (PFS) (P = .61) across the 2 cohorts. No significant association between the use of rituximab and risk of relapse (P = .15) or nonrelapse mortality (P = .12) was observed. Variables independently associated with lower OS included older age at auto-HCT (P < .001), absence of CR at auto-HCT (P < .001) and early chemoimmunotherapy failure (P < .001). Older age (P < .0002) and non-CR pre-HCT (P < .0001) were also associated with inferior PFS. There was no significant difference in early infectious complications between the 2 cohorts. CONCLUSION In this large registry analysis of DLBCL patients undergoing auto-HCT, the addition of rituximab to the BEAM conditioning regimen had no impact on transplantation outcomes. Older age, absence of CR pre auto-HCT, and early chemoimmunotherapy failure were associated with inferior survival.

Published
2020
Full Text
View/download PDF

46. 520 - Impact of Autologous Hematopoietic Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL): A ‘Real-World’ Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

Author

Reves, Heather, Jackson, Meredith, Prasad, Tanushree, Afrough, Aimaz, Anderson, Larry D., Jr., Collins, Robert H., Kaur, Gurbakhash, Wolfe, Heather, Yilmaz, Elif, Khan, Adeel, Kumar, Kiran, Madanat, Yazan F., Vusirikala, Madhuri, Awan, Farrukh T, and Geethakumari, Praveen Ramakrishnan

Published
2023
Full Text
View/download PDF

47. 436 - ‘Real-World’ Impact of Tixagevimab/Cilgavimab (Evusheld) on COVID-19 Outcomes in Patients Undergoing Cellular Therapies

Author

Sannareddy, Aishwarya, Reves, Heather, Narasimhan, Madhusudhanan, Jaleta, Kefyalew, Anderson, Julia Marie, Patel, Hetalkumari, Anderson, Larry D., Jr., Afrough, Aimaz, Chung, Stephen, Collins, Robert H., Kaur, Gurbakhash, Kumar, Kiran A, Madanat, Yazan F., Vusirikala, Madhuri, Awan, Farrukh T, Muthukumar, Alagar R, and Geethakumari, Praveen Ramakrishnan

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results